Funded Startup CEO Salary: Is $900k a Reasonable Figure for a Pre-Revenue Company?
A reader asks whether paying a startup CEO nearly $1 million per year is appropriate when the company has not yet generated revenue.
Context
– The investor backing a biotech startup notes a promising path ahead, including patents pending and positive test results.
– The CEO’s compensation reportedly approaches $1 million annually, despite the company not yet earning revenue.
– The board exists, but all members are described as aligned with the CEO and co-founders.
– The startup recently secured a substantial funding round in the mid-teens of millions and is reportedly close to closing another round of similar size.
– The investor wonders what recourse, if any, exists and seeks opinions from the community.
– Ownership: the CEO holds equity in the company.
Update: Community responses highlighted several points
– The investor occasionally puts capital to work but is not currently looking to deploy new funds; interest lies in acquiring a company to own and operate.
– Background in digital advertising with two successful multi-million exits and one failure.
– Expertise is in digital advertising, B2B sales, and B2C marketing; limited direct knowledge of biotech.
– Residents of the community offered constructive, thoughtful feedback that the investor found valuable.
– Clarification that consulting for other businesses has previously been part of the investor’s portfolio, though that was not the aim of the post.
Takeaways
– CEO compensation in startups, especially pre-revenue, remains a highly debated topic. The appropriateness of a $900k–$1 million salary hinges on factors such as equity stake, vesting terms, level of founder control, stage of the company, and board governance.
– Governance matters: if the board is perceived as aligned with the CEO or lacks independent oversight, compensation decisions can raise questions about alignment of interests between founders, executives, and investors.
– Considerations for investors: evaluate total compensation relative to company milestones, runway, burn rate, and potential upside for remaining stakeholders. Explore whether compensation is performance-based and whether key milestones are clearly tied to remuneration.
– For non-biotech investors or operators: leverage professional advisors to assess compensation structures, equity dilution, and governance protections before engaging further.
If you’re in a similar situation, you might consider:
– Requesting a detailed breakdown of compensation, including salary, bonuses, equity, and any other benefits.
– Seeking independent compensation benchmarking against peer companies at a comparable stage and sector.
– Proposing governance enhancements, such as independent board seats, compensation committees, or clearer milestone-based pay structures.
– Assessing alignment of incentives with long-term value creation for all shareholders.
Would you like this rewritten to fit a specific WordPress blog style guide, such as a more formal corporate tone, SEO-focused headings, or shorter FAQ-style sections?
